Today’s Concepts in EGFR TKIs for NSCLC

Today’s Concepts in EGFR TKIs for NSCLC

Tuesday, March 26, 2019 in San Diego, CA
Breakfast -- San Diego Convention Center, 6:00 AM PT
15AB, Mezzanine Level

Agenda

6:00 AM - 6:30 AM Breakfast and Registration

6:30 AM - 6:40 AM Welcome and Introduction

6:40 AM - 7:00 AM Overview of EGFR-Mutated NSCLC and Pharmacology of EGFR TKIs – Val R. Adams, PharmD, FCCP, BCOP

7:00 AM - 7:20 AM Selecting First-line and Second-line Therapy in the Setting of EGFR-Mutated NSCLC – Matthew Gubens, MD, MS

7:20 AM - 7:40 AM Improving Patient Outcomes and Providing Cost-Effective Care in EGFR-Mutated NSCLC Philip Schwieterman, PharmD, MHA

7:40 AM - 8:00 AM Panel Discussion and Audience Question and Answer Session

Faculty

Program Director
Val Adams, PharmD

Associate Professor
Department of Pharmacy Practice and Science
University of Kentucky
Lexington, Kentucky

Faculty
Matthew Gubens, MD

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Faculty
Philip Schwieterman, PharmD

Director of Oncology and Pediatric Pharmacy
Markey Cancer Center
UK Health Care
Lexington, Kentucky

Goal Statement
The goal of this activity is to educate pharmacists and managed care professionals about advances in the clinical management of patients with EGFR mutation–positive non-small-cell lung cancer.

Target Audience 
This program is intended for pharmacists, managed care professionals, and healthcare providers who care for patients with non-small-cell lung cancer.

Learning Objectives 

  • Examine current recommendations for molecular testing and the roles for liquid biopsies in guiding therapy, especially as it relates to activating and nonactivating EGFR mutations and EGFR T790M mutations
  • Compare current and emerging frontline treatment strategies for advanced EGFR-mutated NSCLC focusing on safety, efficacy, and the individualization of therapy based on tumor-specific and patient-specific factors
  • Compare evidence of efficacy in delaying or reducing brain metastases for the different EGFR TKIs
  • Evaluate current and evolving treatment approaches to address acquired resistance and progression in advanced EGFR-mutated NSCLC
  • Discuss the roles of oncology and managed care pharmacists in optimizing the use of targeted therapy in advanced EGFR-mutated NSCLC, managing therapy-related toxicities, improving adherence, educating patients, and aiding in the implementation of clinical pathways to deliver quality care

Accreditation

Joint Accreditation Statement

Pharmacy Continuing Education

Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CCO designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-19-013-L01-P.

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.